Medicines | Horizonscan geneesmiddelen

Abnobaviscum 900 Durvalumab ^IND Enfortumab vedotin ^IND Erdafitinib Mitomycine extended release

Nivolumab

Extension of indication to include in combination with cisplatin-based chemotherapy the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. ^IND OPDIVO in combination with cisplatin-based chemotherapy is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. ^IND

Sacituzumab Govitecan ^IND Sasanlimab

2-hydroxy Oleic Acid Berubicin Dordaviprone Paclitaxel trevatide Vorasidenib

Abemaciclib ^IND Atezolizumab ^IND

Camizestrant

Camizestrant in combination with CDK4/6 inhibitors for add-on treatment of locoregionally recurrent or metastatic ER-positive, HER2-negative, ESR1-positive Breast cancer in adults and elderly. (SERENA-6) Camizestrant in combination with palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.

Capivasertib

Datopotamab deruxtecan

Datopotamab deruxtecan as monotherapy is indicated for the treatment of adult patients with inoperable or metastatic HR-Positive, HER2-negative Breast Cancer who have been treated with one or two prior lines of systemic chemotherapy. ^IND Datopotamab deruxtecan as monotherapy is indicated for the treatment of adult patients with locally recurrent inoperable or metastatic Triple-Negative Breast Cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. ^IND

Elacestrant

Gedatolisib

Gedatolisib in combination with fulvestrant for second line or later treatment of advanced or metastatic PIK3CA wild-type hormone receptor positive HER2 negative breast cancer in adults and elderly previously treated with CDK4/6 and aromatase inhibitor therapy Gedatolisib in combination with palbociclib and fulvestrant for second line or later treatment of advanced or metastatic PIK3CA mutated Hormone receptor positive HER2 negative breast cancer in adults and elderly previously treated with CDK4/6 and aromatase inhibitor therapy.

Imlunestrant Inavolisib Lasofoxifene Olaparib ^IND Palbociclib ^IND Ribociclib ^IND Sacituzumab govitecan ^IND

Trastuzumab deruxtecan

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens. Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2‑low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy ^IND Extension of indication to include treatment of HER2-low/ultra-low hormone receptor positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting. ^IND

Vepdegestrant

Cadonilimab Durvalumab ^IND Olaparib ^IND Pembrolizumab ^IND Tisotumab vedotin

Fruquintinib Nivolumab ^IND Pembrolizumab / favezelimab Zanzalintinib

Buparlisib Cetuximab sarotalocan Leukocyte interleukin Tislelizumab ^IND Xevinapant

Abexinostat Belzutifan Cabozantinib ^IND Nivolumab/hyaluronidase Ph20 ^IND Zanzalintinib

Atezolizumab ^IND Camrelizumab

Durvalumab

Durvalumab (+/- bevacizumab) in combinatie met TACE in patiënten met locoregionale HCC. ^IND Imfinzi as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). ^IND

Lenvatinib ^IND Namodenoson Nivolumab ^IND Nofazinlimab Tremelimumab

Alectinib ^IND

Amivantamab

Amivantamab in combination with carboplatin and pemetrexed for the first‑line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations. ^IND Amivantamab in combination with lazertinib is indicated for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC). ^IND In combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor. ^IND

Atezolizumab

Subcutaneous formulation of atezolizumab for treatment of PD-(L)-1 Cancer Immunotherapy in multiple tumor types. ^IND Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with advanced NSCLC who are ineligible for platinum-based therapy. ^IND

Aumolertinib (mesilate) Cobolimab Datopotamab deruxtecan Domvanalimab

Durvalumab

Lokaal gevorderd, niet-resectabel NSCLC (stadium III) ^IND Completely resected NSCLC ^IND Limited stage small cell lung cancer (LS-SCLC) following concurrent platinum-based chemotherapy and radiation therapy in combination with Tremelimumab. ^IND Extension of indication to include IMFINZI in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) NSCLC and no known EGFR mutations or ALK rearrangements. ^IND

Encorafenib ^IND Furmonertinib Ivonescimab Lazertinib Lenvatinib ^IND Lurbinectedin Ociperlimab

Osimertinib

Extension of indication to include treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum based chemoradiation therapy. ^IND Osimertinib in combination with pemetrexed and platinum based chemotherapy for locally advanced (clinical stage IIIB, IIIC) or metastatic Non-Small Cell Lung Cancer (NSCLC) (clinical stage IVA or IVB) or recurrent Non-Small Cell Lung Cancer (NSCLC) not amenable to curative surgery or radiotherapy. ^IND Neoadjuvant Osimertinib as Monotherapy or in Combination With Chemotherapy Versus Standard of Care Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer ^IND

Patritumab deruxtecan ^IND Pembrolizumab ^IND Pembrolizumab / vibostolimab Pembrolizumab/hyaluronidase ^IND Retifanlimab ^IND Sacituzumab Govitecan ^IND Serplulimab Sugemalimab Tarlatamab

Tiragolumab

In combination with atezolizumab for first line treatment of locally advanced, unresectable stage III Non-small cell lung cancer in adults and elderly who have no progression during or following concurrent platinum-based chemoradiotherapy. Tiragolumab in combination with Atezolizumab for first line treatment of locally advanced unresectable or metastatic high PD-L1, EGFR-negative, ALK-negative Non-small cell lung cancer in adults and elderly.

Tislelizumab

Tizveni as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab Tizveni in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the first-line treatment of adult patients with squamous non-small cell lung cancer who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC Tizveni in combination with pemetrexed and platinum‑containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous non-small cell lung cancer whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC Locally advanced or metastatic (Stage IIIB or IV), NSCLC (squamous or non-squamous) who have disease progression during or after a platinum-containing regimen. ^IND Extension of indication to include first-line treatment of adult patients with extensive-stage Small Cell Lung Cancer (SCLC) for Tevimbra in combination with etoposide and platinum chemotherapy ^IND

Trastuzumab deruxtecan ^IND Tremelimumab

Cabozantinib ^IND Lutetium (177Lu) edotreotide Lutetium (177Lu) oxodotreotide ^IND Lutetium (177Lu) zadavotide guraxetan Mirdametinib

Afamitresgene autoleucel Belzutifan Bezuclastinib Catequentinib Catumaxomab

Dostarlimab

Extension of indication to include in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability high (MSI H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy ^IND MMRp EC ^IND

Durvalumab ^IND Efbemalenograstim alfa Entrectinib ^IND Ivosidenib Letetresgene autoleucel Melphalan hydrochloride Nirogacestat Ozekibart

Pembrolizumab

Keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first‑line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma. ^IND Keytruda, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy ^IND

Pimicotinib Repotrectinib

Retifanlimab

Patiënten met inoperabele, lokaal gevorderd of gemetastaseerd plaveiselcarcinoom van het anale kanaal. ZYNYZ is geïndiceerd als monotherapie voor de eerstelijnsbehandeling bij volwassen patiënten met gemetastaseerd of recidiverend lokaal gevorderd merkelcelcarcinoom (MCC) dat niet vatbaar is voor curatieve chirurgie of bestraling.

Selinexor ^IND Sugemalimab ^IND Tebentafusp Tislelizumab ^IND

Toripalimab

Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.

Varegacestat Vimseltinib Zanidatamab

Catequentinib Dostarlimab ^IND Mirvetuximab soravtansine Olaparib ^IND

Gemcitabine ^IND Glufosfamide

177Lu-PNT2002 Aglatimagene besadenovec Apalutamide ^IND Atezolizumab ^IND Capivasertib ^IND

Darolutamide

Nubeqa is indicated for the treatment of adult men with metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy . ^IND Extension of indication to include in combination with androgen deprivation therapy (ADT) the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) ^IND

Lutetium (177lu) vipivotide tetraxetan Niraparib ^IND Niraparib-abirateron fixed dose combinatie ^IND Olaparib ^IND Radium-223 ^IND Relugolix Rucaparib ^IND

Talazoparib

Talzenna is indicated in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. ^IND Talzenna in combinatie met enzalutamide is geïndiceerd voor de eerstelijnsbehandeling van patiënten met een gemetastaseerd, hormoonsensitief HRR+ prostaatcarcinoom ^IND

Daromun IO102-IO103 Ipilimumab ^IND Lifileucel Nemvaleukin alfa ^IND Nivolumab/relatlimab/hyaluronidase Ph20 Relatlimab / nivolumab Tucidinostat

Bemarituzumab Ripretinib Tislelizumab ^IND Trastuzumab deruxtecan ^IND Zolbetuximab

Selpercatinib ^IND

MDM2-p53 antagonist Selpercatinib ^IND

Tovorafenib

Oncology

Bladder cancer

Nivolumab

Brain cancer

Breast cancer

Camizestrant

Datopotamab deruxtecan

Gedatolisib

Trastuzumab deruxtecan

Cervical cancer

Colon cancer

Head and neck cancer

Kidney cancer

Liver cancer

Durvalumab

Lung cancer

Amivantamab

Atezolizumab

Durvalumab

Osimertinib

Tiragolumab

Tislelizumab

Neuroendocrine cancer

Oncology other

Dostarlimab

Pembrolizumab

Retifanlimab

Toripalimab

Ovarian cancer

Pancreatic cancer

Prostate cancer

Darolutamide

Talazoparib

Skin cancer

Stomach cancer

Thyroid cancer

Tumour agnostic medication

Unknown

Service

About this site